Preoperative therapy in melanoma: Evolving perspectives in clinical trials
-
Published:2024-01
Issue:
Volume:193
Page:104193
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Kakish HannaORCID,
Xu Kevin,
Ahmed Fasih A.,
Loftus Alexander W.,
Elshami Mohamedraed,
Hoehn Richard S.,
Ammori John B.,
Mangla Ankit,
Rothermel Luke D.
Subject
Oncology,Hematology
Reference58 articles.
1. Trends in melanoma phase 3 clinical trials since 2010: is there hope for advanced melanoma therapies beyond approved treatment mechanisms?;Kakish;Cancers,2022
2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;New Engl. J. Med.,2010
3. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E -mutated melanoma;Chapman;J. Clin. Oncol.,2012
4. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial;Eggermont;Lancet Oncol.,2015
5. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;New Engl. J. Med.,2016